Human OPM2 Xenograft Model
Objective: To assess the in vivo antitumor activity of HuLuc63 humanized antibody targeting CS1 in a human OPM2 myeloma xenograft model in mice
This is a Human OPM2 Xenograft Model protocol using mouse as the model organism. The procedure involves 3 procedural steps, 1 equipment items, 2 materials. Extracted from a 2008 paper published in Clinical Cancer Research.
Model and subjects
mouse • Not specified in provided text • unknown • Not specified in provided text • Not specified in provided text
Study window
Estimated timing pending
Core workflow
Xenograft implantation • HuLuc63 treatment administration • Antitumor activity assessment
Primary readouts
- In vivo antitumor activity of HuLuc63
- Tumor growth inhibition
- NK cell-mediated ADCC activity
- Fc-CD16 interaction efficiency
Key equipment and reagents
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
- Verify the animal model, intervention setup, and collection timepoints against the source paper.
- Check that every direct vendor link matches the exact specification your lab plans to run.
Use the page like this
- Work through the protocol steps in order and use the inline vendor chips only when you need to source or verify an item.
- Jump to Experimental Context for readouts, data shape, and analysis flow before planning downstream analysis.
Protocol Steps
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
Xenograft implantation
Human OPM2 myeloma cells were implanted in mice to establish the xenograft model
Note: This is the foundational step for the in vivo model
View evidence from paper
“in vivo using the human OPM2 xenograft model in mice”
HuLuc63 treatment administration
HuLuc63 antibody was administered to mice bearing OPM2 xenografts to assess antitumor activity
Note: Treatment efficacy depended on Fc-CD16 interaction and presence of NK cells
View evidence from paper
“HuLuc63 exerted significant in vivo antitumor activity, which depended on efficient Fc-CD16 interaction as well as the presence of NK cells in the mice”
Antitumor activity assessment
Evaluation of HuLuc63-mediated antitumor effects in the xenograft model
Note: Activity assessment was conducted in vivo in the xenograft model
View evidence from paper
“HuLuc63-mediated anti-myeloma activity was tested in vitro in antibody-dependent cellular cytotoxicity (ADCC) assays and in vivo using the human OPM2 xenograft model in mice”